The U.S. Food and Drug Administration (FDA) has recommended earlier brain imaging scans to monitor brain swelling before the third infusion of Eisai (OTCPK:ESALF) (OTCPK:ESAIY) and Biogen’s (NASDAQ:BIIB) Alzheimer’s drug Leqembi.

This additional monitoring aims to detect amyloid-related imaging abnormalities